Incyte Adds PD-1 Inhibitor To Its Promising IDO With MacroGenics Deal

Incyte Corp. signaled its intention to boost its immuno-oncology activities on Oct. 25 with the announcement that it was licensing MacroGenics Inc.'s early clinical-stage PD-1 inhibitor, MGA012, for worldwide development and commercialization in all indications, although MacroGenics will retain the right to develop its pipeline assets in combination with MGA012.

Having a PD-1 inhibitor of your own to combine with your other in-house anticancer compounds aids smaller companies avoid losing control to the Big Pharma companies currently marketing checkpoint inhibitors,...